<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://hmg.oxfordjournals.org">
<title>Human Molecular Genetics - current issue</title>
<link>http://hmg.oxfordjournals.org</link>
<description>Human Molecular Genetics - RSS feed of current issue</description>
<prism:eIssn>1460-2083</prism:eIssn>
<prism:coverDisplayDate>15 September 2008</prism:coverDisplayDate>
<prism:publicationName>Human Molecular Genetics</prism:publicationName>
<prism:issn>0964-6906</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2753?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2766?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2776?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2790?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2803?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2819?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2834?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2849?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2863?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2868?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2877?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2886?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2894?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2900?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2910?rss=1" />
  <rdf:li rdf:resource="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2919?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2753?rss=1">
<title><![CDATA[Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2753?rss=1</link>
<description><![CDATA[
<p>Hypertrophic cardiomyopathy (HCM) is a frequent genetic cardiac disease and the most common cause of sudden cardiac death in young individuals. Most of the currently known HCM disease genes encode sarcomeric proteins. Previous studies have shown an association between <I>CSRP3</I> missense mutations and either dilated cardiomyopathy (DCM) or HCM, but all these studies were unable to provide comprehensive genetic evidence for a causative role of <I>CSRP3</I> mutations. We used linkage analysis and identified a <I>CSRP3</I> missense mutation in a large German family affected by HCM. We confirmed <I>CSRP3</I> as an HCM disease gene. Furthermore, <I>CSRP3</I> missense mutations segregating with HCM were identified in four other families. We used a newly designed monoclonal antibody to show that muscle LIM protein (MLP), the protein encoded by <I>CSRP3</I>, is mainly a cytosolic component of cardiomyocytes and not tightly anchored to sarcomeric structures. Our functional data from both <I>in vitro</I> and <I>in vivo</I> analyses suggest that at least one of MLP&rsquo;s mutated forms seems to be destabilized in the heart of HCM patients harbouring a <I>CSRP3</I> missense mutation. We also present evidence for mild skeletal muscle disease in affected persons. Our results support the view that HCM is not exclusively a sarcomeric disease and also suggest that impaired mechano-sensory stress signalling might be involved in the pathogenesis of HCM.</p>
]]></description>
<dc:creator><![CDATA[Geier, C., Gehmlich, K., Ehler, E., Hassfeld, S., Perrot, A., Hayess, K., Cardim, N., Wenzel, K., Erdmann, B., Krackhardt, F., Posch, M. G., Bublak, A., Nagele, H., Scheffold, T., Dietz, R., Chien, K. R., Spuler, S., Furst, D. O., Nurnberg, P., Ozcelik, C.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn160</dc:identifier>
<dc:title><![CDATA[Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2765</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2753</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2766?rss=1">
<title><![CDATA[PTHR1 mutations associated with Ollier disease result in receptor loss of function]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2766?rss=1</link>
<description><![CDATA[
<p>PTHR1-signaling pathway is critical for the regulation of endochondral ossification. Thus, abnormalities in genes belonging to this pathway could potentially participate in the pathogenesis of Ollier disease/Maffucci syndrome, two developmental disorders defined by the presence of multiple enchondromas. In agreement, a functionally deleterious mutation in PTHR1 (p.R150C) was identified in enchondromas from two of six unrelated patients with enchondromatosis. However, neither the p.R150C mutation (26 tumors) nor any other mutation in the <I>PTHR1</I> gene (11 patients) could be identified in another study. To further define the role of PTHR1-signaling pathway in Ollier disease and Maffucci syndrome, we analyzed the coding sequences of four genes (<I>PTHR1</I>, <I>IHH</I>, <I>PTHrP</I> and <I>GNAS1)</I> in leucocyte and/or tumor DNA from 61 and 23 patients affected with Ollier disease or Maffucci syndrome, respectively. We identified three previously undescribed missense mutations in PTHR1 in patients with Ollier disease at the heterozygous state. Two mutations (p.G121E, p.A122T) were present only in enchondromas, and one (p.R255H) in both enchondroma and leukocyte DNA. Assessment of receptor function demonstrated that these three mutations impair PTHR1 function by reducing either the affinity of the receptor for PTH or the receptor expression at the cell surface. These mutations were not found in DNA from 222 controls. Including our data, PTHR1 functionally deleterious mutations have now been identified in five out 31 enchondromas from Ollier patients. These findings provide further support for the idea that heterozygous mutations in PTHR1 that impair receptor function participate in the pathogenesis of Ollier disease in some patients.</p>
]]></description>
<dc:creator><![CDATA[Couvineau, A., Wouters, V., Bertrand, G., Rouyer, C., Gerard, B., Boon, L. M., Grandchamp, B., Vikkula, M., Silve, C.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn176</dc:identifier>
<dc:title><![CDATA[PTHR1 mutations associated with Ollier disease result in receptor loss of function]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2775</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2766</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2776?rss=1">
<title><![CDATA[Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2776?rss=1</link>
<description><![CDATA[
<p>Telomeres and adjacent subtelomeric regions are packaged as heterochromatin in many organisms. The heterochromatic features include DNA methylation, histones H3-Lys9 (Lysine 9) and H4-Lys20 (Lysine 20) methylation and heterochromatin protein1 alpha binding. Subtelomeric DNA is hypomethylated in human sperm and ova, and these regions are subjected to <I>de novo</I> methylation during development. In mice this activity is carried out by DNA methyltransferase 3b (Dnmt3b). Mutations in <I>DNMT3B</I> in humans lead to the autosomal-recessive ICF (immunodeficiency, centromeric region instability, facial anomalies) syndrome. Here we show that, in addition to several satellite and non-satellite repeats, the subtelomeric regions in lymphoblastoid and fibroblast cells of ICF patients are also hypomethylated to similar levels as in sperm. Furthermore, the telomeres are abnormally short in both the telomerase-positive and -negative cells, and many chromosome ends lack detectable telomere fluorescence <I>in situ</I> hybridization signals from either one or both sister-chromatids. In contrast to Dnmt3a/b<sup>&ndash;/&ndash;</sup> mouse embryonic stem cells, increased telomere sister-chromatid exchange was not observed in ICF cells. Hypomethylation of subtelomeric regions was associated in the ICF cells with advanced telomere replication timing and elevated levels of transcripts emanating from telomeric regions, known as TERRA (telomeric-repeat-containing RNA) or TelRNA. The current findings provide a mechanistic explanation for the abnormal telomeric phenotype observed in ICF syndrome and highlights the link between TERRA/TelRNA and structural telomeric integrity.</p>
]]></description>
<dc:creator><![CDATA[Yehezkel, S., Segev, Y., Viegas-Pequignot, E., Skorecki, K., Selig, S.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn177</dc:identifier>
<dc:title><![CDATA[Hypomethylation of subtelomeric regions in ICF syndrome is associated with abnormally short telomeres and enhanced transcription from telomeric regions]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2789</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2776</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2790?rss=1">
<title><![CDATA[Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2790?rss=1</link>
<description><![CDATA[
<p>Friedreich's ataxia is a neurodegenerative disease caused by reduced expression of the mitochondrial protein frataxin. The main phenotypic features of frataxin-deficient human and yeast cells include iron accumulation in mitochondria, iron-sulphur cluster defects and high sensitivity to oxidative stress. Glutathione is a major protective agent against oxidative damage and glutathione-related systems participate in maintaining the cellular thiol/disulfide status and the reduced environment of the cell. Here, we present the first detailed biochemical study of the glutathione-dependent redox status of wild-type and frataxin-deficient cells in a yeast model of the disease. There were five times less total glutathione (GSH+GSSG) in frataxin-deficient cells, imbalanced GSH/GSSG pools and higher glutathione peroxidase activity. The pentose phosphate pathway was stimulated in frataxin-deficient cells, glucose-6-phosphate dehydrogenase activity was three times higher than in wild-type cells and this was coupled to a defect in the NADPH/NADP<sup>+</sup> pool. Moreover, analysis of gene expression confirms the adaptative response of mutant cells to stress conditions and we bring evidence for a strong relation between the glutathione-dependent redox status of the cells and iron homeostasis. Dynamic studies show that intracellular glutathione levels reflect an adaptation of cells to iron stress conditions, and allow to distinguish constitutive stress observed in frataxin-deficient cells from the acute response of wild-type cells. In conclusion, our findings provide evidence for an impairment of glutathione homeostasis in a yeast model of Friedreich's ataxia and identify glutathione as a valuable indicator of the redox status of frataxin-deficient cells.</p>
]]></description>
<dc:creator><![CDATA[Auchere, F., Santos, R., Planamente, S., Lesuisse, E., Camadro, J.-M.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn178</dc:identifier>
<dc:title><![CDATA[Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2802</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2790</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2803?rss=1">
<title><![CDATA[Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2803?rss=1</link>
<description><![CDATA[
<p>Human <I>HNRNPGT</I>, encoding the protein hnRNP G-T, is one of several autosomal retrogenes derived from <I>RBMX</I>. It has been suggested that <I>HNRNPGT</I> functionally replaces the sex-linked <I>RBMX</I> and <I>RBMY</I> genes during male meiosis. We show here that during normal mouse germ cell development, hnRNP G-T protein is strongly expressed during and after meiosis when proteins expressed from <I>Rbmx</I> or <I>Rbmx</I>-like genes are absent. Amongst these <I>Rbmx</I>-like genes, DNA sequence analyses indicate that two other mouse autosomal <I>Rbmx</I>-derived retrogenes have evolved recently in rodents and one already shows signs of degenerating into a non-expressed pseudogene. In contrast, orthologues of <I>Hnrnpgt</I> are present in all four major groups of placental mammals. The sequence of <I>Hnrnpgt</I> is under considerable positive selection suggesting it performs an important germ cell function in eutherians. To test this, we inactivated <I>Hnrnpgt</I> in ES cells and studied its function during spermatogenesis in chimaeric mice. Although germ cells heterozygous for this targeted allele could produce sperm, they did not contribute to the next generation. Chimaeric mice with a high level of mutant germ cells were infertile with low sperm counts and a high frequency of degenerate seminiferous tubules and abnormal sperm. Chimaeras made from a 1:1 mix of targeted and wild-type ES cell clones transmitted wild-type germ cells only. Our data show that haploinsufficiency of <I>Hnrnpgt</I> results in abnormal sperm production in the mouse. Genetic defects resulting in reduced levels of <I>HNRNPGT</I> could, therefore, be a cause of male infertility in humans.</p>
]]></description>
<dc:creator><![CDATA[Ehrmann, I., Dalgliesh, C., Tsaousi, A., Paronetto, M. P., Heinrich, B., Kist, R., Cairns, P., Li, W., Mueller, C., Jackson, M., Peters, H., Nayernia, K., Saunders, P., Mitchell, M., Stamm, S., Sette, C., Elliott, D. J.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn179</dc:identifier>
<dc:title><![CDATA[Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2818</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2803</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2819?rss=1">
<title><![CDATA[Loss of polycystin-1 causes centrosome amplification and genomic instability]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2819?rss=1</link>
<description><![CDATA[
<p>Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenetic disease predominantly caused by alteration or dysregulation of the <I>PKD1</I> gene, which encodes polycystin-1 (PC1). The disease is characterized by the progressive expansion of bilateral fluid-filled renal cysts that ultimately lead to renal failure. Individual cysts, even within patients with germline mutations, are genetically heterogeneous, displaying diverse chromosomal abnormalities. To date, the molecular mechanisms responsible for this genetic heterogeneity remain unknown. Using a lentiviral-mediated siRNA expression model of <I>Pkd1</I> hypomorphism, we show that loss of PC1 function is sufficient to produce centrosome amplification and multipolar spindle formation. These events lead to genomic instability characterized by gross polyploidism and mitotic catastrophe. Following these dramatic early changes, the cell population rapidly converges toward a stable ploidy in which centrosome amplification is significantly decreased, though cytological abnormalities such as micronucleation, chromatin bridges and aneuploidy remain common. In agreement with our <I>in vitro</I> findings, we provide the first <I>in vivo</I> evidence that significant centrosome amplification occurs in kidneys from conditional <I>Pkd1</I> knockout mice at early and late time during the disease progression as well as in human ADPKD patients. These findings establish a novel function of PC1 in ADPKD pathogenesis and a genetic mechanism that may underlie the intrafamilial variability of ADPKD progression.</p>
]]></description>
<dc:creator><![CDATA[Battini, L., Macip, S., Fedorova, E., Dikman, S., Somlo, S., Montagna, C., Gusella, G. L.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn180</dc:identifier>
<dc:title><![CDATA[Loss of polycystin-1 causes centrosome amplification and genomic instability]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2833</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2819</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2834?rss=1">
<title><![CDATA[Nicotinic acetylcholine receptor {beta}2 subunit gene implicated in a systems-based candidate gene study of smoking cessation]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2834?rss=1</link>
<description><![CDATA[
<p>Although the efficacy of pharmacotherapy for tobacco dependence has been previously demonstrated, there is substantial variability among individuals in treatment response. We performed a systems-based candidate gene study of 1295 single nucleotide polymorphisms (SNPs) in 58 genes within the neuronal nicotinic receptor and dopamine systems to investigate their role in smoking cessation in a bupropion placebo-controlled randomized clinical trial. Putative functional variants were supplemented with tagSNPs within each gene. We used global tests of main effects and treatment interactions, adjusting the <I>P</I>-values for multiple correlated tests. An SNP (rs2072661) in the 3' UTR region of the &beta;2 nicotinic acetylcholine receptor subunit (<I>CHRNB2</I>) has an impact on abstinence rates at the end of treatment (adjusted <I>P</I> = 0.01) and after a 6-month follow-up period (adjusted <I>P</I> = 0.0002). This latter <I>P</I>-value is also significant with adjustment for the number of genes tested. Independent of treatment at 6-month follow-up, individuals carrying the minor allele have substantially decreased the odds of quitting (OR = 0.31; 95% CI 0.18&ndash;0.55). Effect of estimates indicate that the treatment is more effective for individuals with the wild-type (OR = 2.14, 95% CI 1.20&ndash;3.81) compared with individuals carrying the minor allele (OR = 0.83, 95% CI 0.32&ndash;2.19), although this difference is only suggestive (<I>P</I> = 0.10). Furthermore, this SNP demonstrated a role in the time to relapse (<I>P</I> = 0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (<I>P</I> = 0.0009). Overall, while our results indicate strong evidence for <I>CHRNB2</I> in ability to quit smoking, these results require replication in an independent sample.</p>
]]></description>
<dc:creator><![CDATA[Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., Lerman, C., for the Pharmacogenetics of Nicotine Addiction and Treatment Consortium]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn181</dc:identifier>
<dc:title><![CDATA[Nicotinic acetylcholine receptor {beta}2 subunit gene implicated in a systems-based candidate gene study of smoking cessation]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2848</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2834</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2849?rss=1">
<title><![CDATA[A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2849?rss=1</link>
<description><![CDATA[
<p>Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition characterized by progressive motor neuron degeneration and muscle paralysis. Genetic evidence from man and mouse has indicated that mutations in the dynein/dynactin motor complex are correlated with motor neuron degeneration. In this study, we have generated transgenic mice with neuron-specific expression of Bicaudal D2 N-terminus (BICD2-N) to chronically impair dynein/dynactin function. Motor neurons expressing BICD2-N showed accumulation of dynein and dynactin in the cell body, Golgi fragmentation and several signs of impaired retrograde trafficking: the appearance of giant neurofilament swellings in the proximal axon, reduced retrograde labelling by tracer injected in the muscle and delayed expression of the injury transcription factor ATF3 after axon transection. Despite these abnormalities, BICD2-N mice did not develop signs of motor neuron degeneration and motor abnormalities. Interestingly, the BICD2-N transgene increased lifespan in &lsquo;low copy&rsquo; SOD1-G93A ALS transgenic mice. Our findings indicate that impaired dynein/dynactin function can explain several pathological features observed in ALS patients, but may be beneficial in some forms of ALS.</p>
]]></description>
<dc:creator><![CDATA[Teuling, E., van Dis, V., Wulf, P. S., Haasdijk, E. D., Akhmanova, A., Hoogenraad, C. C., Jaarsma, D.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn182</dc:identifier>
<dc:title><![CDATA[A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2862</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2849</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2863?rss=1">
<title><![CDATA[Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2863?rss=1</link>
<description><![CDATA[
<p>Alzheimer's disease (AD) and Parkinson's disease (PD), the two most common neurodegenerative disorders in the elderly, have been hypothesized to share genetic determinants. Recently, Li <I>et al</I>. proposed that a variant in the <I>NEDD9</I> gene may be one of these common genetic factors. We attempted to confirm this initial observation by conducting an equivalent analysis in terms of pathologies and sample size. We genotyped the <I>NEDD9</I> rs760678 SNP in three independent AD case&ndash;control studies (<I>n</I> = 3176) and two independent PD case&ndash;control studies (<I>n</I> = 1855). However, we failed to detect an association of this SNP with the risk of developing AD or PD, in any of these populations. In conclusion, these data indicate that the rs760678 SNP of the <I>NEDD9</I> gene is at best a weak genetic determinant of AD or PD.</p>
]]></description>
<dc:creator><![CDATA[Chapuis, J., Moisan, F., Mellick, G., Elbaz, A., Silburn, P., Pasquier, F., Hannequin, D., Lendon, C., Campion, D., Amouyel, P., Lambert, J.-C.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn183</dc:identifier>
<dc:title><![CDATA[Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2867</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2863</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2868?rss=1">
<title><![CDATA[A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2868?rss=1</link>
<description><![CDATA[
<p>Systemic lupus erythematosus (SLE) is the prototype autoimmune disease where genes regulated by type I interferon (IFN) are over-expressed and contribute to the disease pathogenesis. Because signal transducer and activator of transcription 4 (<I>STAT4</I>) plays a key role in the type I IFN receptor signaling, we performed a candidate gene study of a comprehensive set of single nucleotide polymorphism (SNPs) in <I>STAT4</I> in Swedish patients with SLE. We found that 10 out of 53 analyzed SNPs in <I>STAT4</I> were associated with SLE, with the strongest signal of association (<I>P</I> = 7.1 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;8</sup>) for two perfectly linked SNPs rs10181656 and rs7582694. The risk alleles of these 10 SNPs form a common risk haplotype for SLE (<I>P</I> = 1.7 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>). According to conditional logistic regression analysis the SNP rs10181656 or rs7582694 accounts for all of the observed association signal. By quantitative analysis of the allelic expression of <I>STAT4</I> we found that the risk allele of <I>STAT4</I> was over-expressed in primary human cells of mesenchymal origin, but not in B-cells, and that the risk allele of <I>STAT4</I> was over-expressed (<I>P</I> = 8.4 <FONT FACE="arial,helvetica">x</FONT> 10<sup>&ndash;5</sup>) in cells carrying the risk haplotype for SLE compared with cells with a non-risk haplotype. The risk allele of the SNP rs7582694 in <I>STAT4</I> correlated to production of anti-dsDNA (double-stranded DNA) antibodies and displayed a multiplicatively increased, 1.82-fold risk of SLE with two independent risk alleles of the <I>IRF5</I> (interferon regulatory factor 5) gene.</p>
]]></description>
<dc:creator><![CDATA[Sigurdsson, S., Nordmark, G., Garnier, S., Grundberg, E., Kwan, T., Nilsson, O., Eloranta, M.-L., Gunnarsson, I., Svenungsson, E., Sturfelt, G., Bengtsson, A. A., Jonsen, A., Truedsson, L., Rantapaa-Dahlqvist, S., Eriksson, C., Alm, G., Goring, H. H.H., Pastinen, T., Syvanen, A.-C., Ronnblom, L.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn184</dc:identifier>
<dc:title><![CDATA[A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2876</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2868</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2877?rss=1">
<title><![CDATA[ATP modulates PTEN subcellular localization in multiple cancer cell lines]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2877?rss=1</link>
<description><![CDATA[
<p>The tumour suppressor gene <I>PTEN</I> plays an important somatic role in both hereditary and sporadic breast carcinogenesis. While the role of PTEN's lipid phosphatase activity, as a negative regulator of the cytoplasmic phosphatidylinositol-3-kinase/Akt pathway is well known, it is now well established that PTEN exists and functions in the nucleus. Multiple mechanisms of regulating PTEN's subcellular localization have been reported. However none are ubiquitous across multiple cancer cell lines and tissue types. We show here that adenosine triphosphate (ATP) regulates PTEN subcellular localization in a variety of different cancer cell lines, including those derived from breast, colon and thyroid carcinomas. Cells deficient in ATP show an increased level of nuclear PTEN protein. This increase in PTEN is reversed when cells are supplemented with ATP, ADP or AMP. In contrast, the addition of the non-hydrolyzable analogue ATPS, did not reverse nuclear PTEN protein levels in all the cell types tested. To our knowledge, this is the first report that describes a regulation of PTEN subcellular localization that is not specific to one cell line or tissue type, but appears to be common across a variety of cell lineages.</p>
]]></description>
<dc:creator><![CDATA[Lobo, G. P., Waite, K. A., Planchon, S. M., Romigh, T., Houghton, J. A., Eng, C.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn185</dc:identifier>
<dc:title><![CDATA[ATP modulates PTEN subcellular localization in multiple cancer cell lines]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2885</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2877</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2886?rss=1">
<title><![CDATA[NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2886?rss=1</link>
<description><![CDATA[
<p>Congenital aortic valve stenosis (AVS), coarctation of the aorta (COA) and hypoplastic left heart syndrome (HLHS) are congenital cardiovascular malformations that all involve the left ventricular outflow tract (LVOT). They are presumably caused by a similar developmental mechanism involving the developing endothelium. The exact etiology for most LVOT malformations is unknown, but a strong genetic component has been established. We demonstrate here that mutations in the gene <I>NOTCH1</I>, coding for a receptor in a developmentally important signaling pathway, are found across the spectrum of LVOT defects. We identify two specific mutations that reduce ligand (JAGGED1) induced NOTCH1 signaling. One of these mutations perturbs the S1 cleavage of the receptor in the Golgi. These findings suggest that the levels of NOTCH1 signaling are tightly regulated during cardiovascular development, and that relatively minor alterations may promote LVOT defects. These results also establish for the first time that AVS, COA and HLHS can share a common pathogenetic mechanism at the molecular level, explaining observations of these defects co-occurring within families.</p>
]]></description>
<dc:creator><![CDATA[McBride, K. L., Riley, M. F., Zender, G. A., Fitzgerald-Butt, S. M., Towbin, J. A., Belmont, J. W., Cole, S. E.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn187</dc:identifier>
<dc:title><![CDATA[NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2893</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2886</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2894?rss=1">
<title><![CDATA[Polygenic determinants of severe hypertriglyceridemia]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2894?rss=1</link>
<description><![CDATA[
<p>Recent genome-wide association (GWA) studies have identified new genetic determinants of complex quantitative traits, including plasma triglyceride (TG). We hypothesized that common variants associated with mild TG variation identified in GWA studies would also be associated with severe hypertriglyceridemia (HTG). We studied 132 patients of European ancestry with severe HTG (fasting plasma TG &gt; 10 mmol/l), who had no mutations found by resequencing of candidate genes, and 351 matched normolipidemic controls. We determined genotypes for: <I>GALNT2</I> rs4846914, <I>TBL2/MLXIPL</I> rs17145738, <I>TRIB1</I> rs17321515, <I>ANGPTL3</I> rs12130333, <I>GCKR</I> rs780094, <I>APOA5</I> rs3135506 (S19W), <I>APOA5</I> rs662799 (&ndash;1131T &gt; C), <I>APOE</I> (isoforms) and <I>LPL</I> rs328 (S447X). We found that: (i) genotypes, including those of <I>APOA5</I> S19W, <I>APOA5</I> &ndash;1131T &gt; C, <I>APOE</I>, <I>GCKR</I>, <I>TRIB1</I> and <I>TBL2/MLXIPL</I>, were significantly associated with severe HTG; (ii) odds ratios for these genetic variables were significant in both univariate and multivariate regression analyses, irrespective of the presence or absence of diabetes or obesity; (iii) a significant fraction&mdash;about one-quarter&mdash;of the explained variation in disease status was associated with these genotypes. Therefore, common SNPs (single nucleotide polymorphisms) that are associated with mild TG variation in GWA studies of normolipidemic subjects are also associated with severe HTG. Our findings are consistent with the emerging model of a complex genetic trait. At the extremes of a quantitative trait, such as severe HTG, are found the cumulative contributions of both multiple rare alleles with large genetic effects and common alleles with small effects.</p>
]]></description>
<dc:creator><![CDATA[Wang, J., Ban, M. R., Zou, G. Y., Cao, H., Lin, T., Kennedy, B. A., Anand, S., Yusuf, S., Huff, M. W., Pollex, R. L., Hegele, R. A.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn188</dc:identifier>
<dc:title><![CDATA[Polygenic determinants of severe hypertriglyceridemia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2899</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2894</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2900?rss=1">
<title><![CDATA[Embryonic motor axon development in the severe SMA mouse]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2900?rss=1</link>
<description><![CDATA[
<p>Spinal muscular atrophy (SMA) is caused by reduced levels of survival motor neuron (SMN) protein. Previously, cultured SMA motor neurons showed reduced growth cone size and axonal length. Furthermore, reduction of SMN in zebrafish resulted in truncation followed by branching of motor neuron axons. In this study, motor neurons labeled with green fluorescent protein (GFP) were examined in SMA mice from embryonic day 10.5 to postnatal day 2. SMA motor axons showed no defect in axonal formation or outgrowth at any stage of development. However, a significant increase in synapses lacking motor axon input was detected in embryonic SMA mice. Therefore, one of the earliest detectable morphological defects in the SMA mice is the loss of synapse occupation by motor axons. This indicates that in severe SMA mice there are no defects in motor axon formation however, we find evidence of denervation in embryogenesis.</p>
]]></description>
<dc:creator><![CDATA[McGovern, V. L., Gavrilina, T. O., Beattie, C. E., Burghes, A. H.M.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn189</dc:identifier>
<dc:title><![CDATA[Embryonic motor axon development in the severe SMA mouse]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2909</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2900</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2910?rss=1">
<title><![CDATA[Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2910?rss=1</link>
<description><![CDATA[
<p>Somatic microindels (microdeletions with microinsertions) have been studied in normal mouse tissues using the Big Blue <I>lacI</I> transgenic mutation detection system. Here we analyze microindels in human cancers using an endogenous and transcribed gene, the <I>TP53</I> gene. Microindel frequency, the enhancement of 1&ndash;2 microindels and other features are generally similar to that observed in the non-transcribed <I>lacI</I> gene in normal mouse tissues. The current larger sample of somatic microindels reveals recurroids: mutations in which deletions are identical and the co-localized insertion is similar. The data reveal that the inserted sequences derive from nearby but not adjacent sequences in contrast to the slippage that characterizes the great majority of pure microinsertions. The microindel inserted sequences derive from a template on the sense or antisense strand with similar frequency. The estimated error rate of the insertion process of 13% per bp is by far the largest reported <I>in vivo</I>, with the possible exception of somatic hypermutation in the immunoglobulin gene. The data constrain possible mechanisms of microindels and raise the question of whether microindels are &lsquo;scars&rsquo; from the bypass of large DNA adducts by a translesional polymerase, e.g. the &lsquo;Tarzan model&rsquo; presented herein.</p>
]]></description>
<dc:creator><![CDATA[Scaringe, W. A., Li, K., Gu, D., Gonzalez, K. D., Chen, Z., Hill, K. A., Sommer, S. S.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn190</dc:identifier>
<dc:title><![CDATA[Somatic microindels in human cancer: the insertions are highly error-prone and derive from nearby but not adjacent sense and antisense templates]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2918</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2910</prism:startingPage>
<prism:section>ARTICLES</prism:section>
</item>

<item rdf:about="http://hmg.oxfordjournals.org/cgi/content/short/17/18/2919?rss=1">
<title><![CDATA[A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis]]></title>
<link>http://hmg.oxfordjournals.org/cgi/content/short/17/18/2919?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Martin, D. C., Atmuri, V., Hemming, R. J., Farley, J., Mort, J. S., Byers, S., Hombach-Klonisch, S., Csoka, A. B., Stern, R., Triggs-Raine, B. L.]]></dc:creator>
<dc:date>2008-08-26</dc:date>
<dc:identifier>info:doi/10.1093/hmg/ddn207</dc:identifier>
<dc:title><![CDATA[A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:number>18</prism:number>
<prism:volume>17</prism:volume>
<prism:endingPage>2919</prism:endingPage>
<prism:publicationDate>2008-09-15</prism:publicationDate>
<prism:startingPage>2919</prism:startingPage>
<prism:section>CORRIGENDUM</prism:section>
</item>

</rdf:RDF>